Renz A, Hohner M, Jami R, Breitenbach M, Josephs-Spaulding J, Dürrwald J, Best L, Dulière V, Mialon C, Bader SM, Marinos G, Leonidou N, Cabreiro F, Pellegrini M, Doerflinger M, Rosa-Calatrava M, Pizzorno A, Dräger A, Schindler M, Kaleta C. Metabolic modeling elucidates phenformin and atpenin A5 as broad-spectrum antiviral 2 drugs against RNA viruses. Communication Biology 2025 8:791
https://www.nature.com/articles/s42003-025-08148-y
Lee CY, Huang C-W De Falco L, Adawiyah Binte Minhat RA, Traversier A, Wang B, Mohd Salleh SN, Xian Ngoh EZ, Huang Y, KimJ, Zirui Tay M, Rosa-Calatrava M, Pizzorno A, Huber RG, Wang C-I. A Combinatorial and Computational Tandem Approach towards a Universal Therapeutics against ACE2-Mediated Coronavirus Infections. iScience 16 May 2025, 112687
https://www.cell.com/iscience/fulltext/S2589-0042(25)00948-4?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2589004225009484%3Fshowall%3Dtrue
Rivollier P, Richard E, Hoang A, Traversier A, Rosa-Calatrava M, Jary D, Texier I, Fort S. Chemical modification of sialylated oligosaccharides to functionalize nanostructured lipid carriers: a comparative approach. Organic & Biomolecular Chemistry 2025 May
https://pubs.rsc.org/en/Content/ArticleLanding/2025/OB/D5OB00270B
Padey B, Droillard C, Dulière V, Fouret J, Nicolas de Lamballerie C, Milesi C, Laurent E, Brun P, Traversier A, Julien T, Terrier O, Rosa-Calatrava M*, Pizzorno A*. Host-directed repurposed diltiazem enhances the antiviral activity of classic antivirals against influenza and SARS-CoV-2. Antiviral Research 2025 May:237:106138.
https://www.sciencedirect.com/science/article/pii/S0166354225000646?via%3Dihub
Pereira De Oliveira R, Droillard C, Devouassoux G, Rosa-Calatrava M. In vitro models to study viral-induced asthma exacerbation: a short review for a key issue. Frontiers in Allergy 2025 Mar 28;6:1530122.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11987631/
Ferreira Lopes C, Laurent E, Caul-Futy M, Dubois J, Mialon C, Chojnacki C, Sage E, Boda B, Huang S, Rosa-Calatrava M*, Constant S*. A novel in vitro primary human alveolar model (AlveolAir™) for H1N1 and SARS-CoV-2 infection and antiviral screening. Microorganisms 2025 Mar 3;13(3):572.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11944821/pdf/microorganisms-13-00572.pdf
Oliva J, Ruffin M, Calmel C, Gibeaud A, Pizzorno A, Gaudin C, Chardonnet S, de Almeida Bastos V, Rosa-Calatrava M, Soulé A, Emad A, Rousseau S, Corvol H, Terrier O, Guillot L. Divergent responses to SARS-CoV-2 infection in bronchial epithelium with pre-existing respiratory diseases. iScience 2025 Feb 12;28(3):111999.
https://pmc.ncbi.nlm.nih.gov/articles/PMC11914195/
Yaugel-Novoa M, Noaillya B, Jospina F, Pizzorno A, Traversier T, Pozzetto B, Waeckel L, Longet S, Pillet S, Botelho-Nevers E, Rosa-Calatrava M, Bourlet T and Paul S. Impaired mucosal IgA response in patients with severe COVID-19. Emerging Microbes & Infections 2024 december VOL. 13, 2401940
https://pubmed.ncbi.nlm.nih.gov/39358866/
Gonzales Gomez Catalina, Rosa-Calatrava M and Fouret J. Optimizing in silico drug discovery: simulation of connected differential expression signatures and applications to benchmarking. Briefings in Bioinformatics 2024 May 23;25(4)
https://pubmed.ncbi.nlm.nih.gov/38935068/
Ogonczyk-Makowska D, Brun P, Vacher C, Pizzorno A, Chupin C, Droillard C, Laurent E, Duliere V, Traversier A, Terrier O, Julien T, Galloux M, Paul S, Eléouët JF, Hamelin ME, Boivin G, Rosa-Calatrava M and Dubois J. New mucosal bivalent live-attenuated vaccine is highly efficient to protect against human metapneumovirus and RSV. NPJ Vaccines 2024 Jun 19;9(1):111 9:111
https://pubmed.ncbi.nlm.nih.gov/38898106/
Prenafeta A, Bech-Sàbat G, Moros A, Barreiro A, Fernández A, Cañete M, Roca M, González-González L, Garriga C, Confais J, Toussenot M, Contamin H, Pizzorno A, Rosa-Calatrava M, Pradenas E, Marfil S, Blanco S, Cebollada Rica P, Sisteré-Oró M, Meyerhans A, Lorca C, Segalés J, Prat T, March R and Ferrer L. Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non- human primates. Iscience 2023 June 27
https://pubmed.ncbi.nlm.nih.gov/37502366/
Fausther-Bovendo H, Hamelin ME, Carbonneau J, Venable MC, Checkmahomed L, Lavoie PO, Ouellet MÈ, Boivin G, D'Aoust MA, Kobinger GP. A Candidate Therapeutic Monoclonal Antibody Inhibits Both HRSV and HMPV Replication in Mice. Biomedicines. 2022 Oct 8;10(10):2516.
https://pubmed.ncbi.nlm.nih.gov/36289776/
Ogonczyk Makowska D, Hamelin MÈ, Boivin G. Engineering of Live Chimeric Vaccines against Human Metapneumovirus. Pathogens. 2020 Feb 19;9(2):135.
https://pubmed.ncbi.nlm.nih.gov/32093057/
Barateau V, Peyrot L, Saade C, Pozzetto B, Brengel-Pesce K, Elsensohn M, Allative O, Guibert N, Compagnon C, Mariano N, Chaix J, Djebali S, Fassier JL, Lina B, Lefsihane K, Espi M, Thaunat O, Marvel J, Rosa-Calatrava M, Pizzorno MA, Maucort-boulch D, Henaff L, Elahi M, Vanhems P, Paul S, Walzer T, Assant S and Defrance T. Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination. Science Translational Medecine. 2023 Mar 15;15(687)
https://pubmed.ncbi.nlm.nih.gov/36921035/
Zhang Q#, Pizzorno A#, Miorin L, Bastard P, Gervais A, Le Voyer T, Bizien L, Manry J, Rosain J, Philippot Q, Goavec K, Padey B, Cupic A, Laurent E, Saker K, Vanker M, Särekannu K; COVID Human Genetic Effort; Etablissement Français du Sang Study Group; Constances Cohort; 3C-Dijon Study; Cerba HealthCare Group; Lyon Antigrippe Working Group; REIPI INF Working Group; et al., Casalegno JS, Queromes G, Argaud L, Javouhey E, Rosa-Calatrava M, Cordero E, Aydillo T, Medina RA, Kisand K, Puel A, Jouanguy E, Abel L, Cobat A, Trouillet-Assant S, García-Sastre A, Casanova JL. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. Journal of Experimental Medecine. 2022 Nov 7;219(11). # equal contribution
https://pmc.ncbi.nlm.nih.gov/articles/PMC9485705/
Nantel S, Bourdin B, Adams K, et al., Boivin G, Quach C, Decaluwe H. Symptomatology During Previous SARS-CoV-2 Infection and Serostatus Before Vaccination Influences the Immunogenicity of BNT162b2 COVID-19 mRNA Vaccine. Frontiers in Immunology. 2022; 13:930252.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9614167/
Checkmahomed L, Carbonneau J, Du Pont V, Riola NC, Perry JK, Li J, Paré B, Simpson SM, Smith MA, Porter DP, Boivin G. In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance. Antimicrobial Agents and Chemotherapy. 2022; 66:e0019822.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9295571/
Piret J, Goyette N, Boivin G. In Vitro Activity of Letermovir Against Human Cytomegalovirus Isolates with Different Drug Susceptibility Phenotypes. Antiviral Research. 2022; 202:105328.
https://www.sciencedirect.com/science/article/abs/pii/S0166354222000973?via%3Dihub
Tardif JC, Cossette M, Guertin MC, Bouabdallaoui N, Dubé MP, Boivin G. Predictive Risk Factors for Hospitalization and Response to Colchicine in Patients with COVID-19. International Journal of Infectious Diseases. 2022; 116:387-390.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8758567/
Marlin R, Desjardins D, Contreras V, Lingas G, Solas C, Roques P, Naninck T, Pascal Q, Behillil S, Maisonnasse P, Lemaitre J, Kahlaoui N, Delache B, Pizzorno A, Nougairede A, Ludot C, Terrier O, Dereuddre-Bosquet N, Relouzat F, Chapon C, Ho Tsong Fang R, van der Werf S, Rosa Calatrava M, Malvy D, de Lamballerie X, Guedj J, Le Grand R. Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates. Nature Communication. 2022 Aug 30;13(1):5108.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9427089/
Pizzorno A, Padey B, Mouton W, Oliva J, Trouillet-Assant S, Rosa-Calatrava M# and Terrier O#. Interactions Between SARS-CoV-2 Replication and Major Respiratory Viruses in Human Nasal Epithelium. Journal of Infectious Diseases. 2022 Aug 29;jiac357. #equal contribution
https://pmc.ncbi.nlm.nih.gov/articles/PMC9452145/
Jonsdottir HR, Siegrist D, Julien T, Padey T, Bouveret M, Terrier O, Pizzorno A, Huang S, Samby K, Wells TNC, Boda B#, Rosa-Calatrava M#, Engler O# and Constant S#. Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro. Biomedicine & Pharmacotherapy 150 Volume 150 June 2022, 113058.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9057985/
Chupin C, Pizzorno A, Traversier A, Brun P, Ogonczyk-Makowska D, Padey B, Milesi C, Dulière V, Laurent E, Julien T, Galloux M, Lina B, Eléouët JF, Moreau K, Hamelin ME, Terrier O, Boivin G, Dubois J and Rosa-Calatrava M. Avian Cell Line DuckCelt-T17 Is an Efficient Production System for Live-Attenuated Human Metapneumovirus Vaccine Candidate Metavac. NPJ Vaccines 2021 Oct 16;9(10):1190
https://pmc.ncbi.nlm.nih.gov/articles/PMC8540687/
Tardif J-C, Bouabdallaoui N, L’Allier PL… and Boivin G. Colchicine for Community-Treated Patients with COVID-19: A Randomised, Double-Blinded, Adaptive, Controlled Trial. The Lancet Respiratory Medicine. 2021; 9:924-932.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8159193/
Bei Wang, Daniel Asarnow, Wen-Hsin Lee#, Ching-Wen Huang#, Bryan Faust#, Patricia Miang Lon Ng#, Eve Zi Xian Ngoh#, Markus Bohn#, David Bulkley#, Andrés Pizzorno#, Hwee Ching Tan, Chia Yin Lee, Rabiatul Adawiyah Minhat, Olivier Terrier, Mun Kuen Soh, Frannie Jiuyi Teo, Yvonne Yee Chin Yeap, Yuanyu Hu, Shirley Gek Kheng Seah, Sebastian Maurer-Stroh, Laurent Renia, Brendon John Hanson, Manuel Rosa-Calatrava, Aashish Manglik, Yifan Cheng, Charles S. Craik, Cheng-I Wang. Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia. 2021 Cell. Jun 10;184(12):3192-3204.e16. #equal contribution
https://pmc.ncbi.nlm.nih.gov/articles/PMC8064868/
Lopez J#, Mommert M#, Mouton W#, Pizzorno A#, Brengel-Pesce K, Mezidi M, Villard M, Lina B, Richard JC, Cheynet V, Padey B, Duliere V, Julien T, Paul S, Bastard P, Casanova JL, Rosa-Calatrava M, Morfin F, Walzer T and Trouillet-Assant S. Early nasal type I IFN immunity against SARS-CoV2 is compromised in patients with autoantibodies against type I IFNs. Journal Experimental Medecine 2021 Oct 4;218(10)
https://pmc.ncbi.nlm.nih.gov/articles/PMC8352718/
Abed Y, Mamoun AS, Boivin G. Fitness of Baloxavir-Resistant Influenza A and B Viruses: A Mini Review. Reviews in Medical Virology. 2021:e2175.
https://pubmed.ncbi.nlm.nih.gov/32975358/
Abed Y, Checkmahomed L, Fage C, M’hamdi Z, Venable M-C, Boivin G. Characterization of Contemporary Influenza B Recombinant Viruses Harboring Mutations of Reduced Susceptibility to Baloxavir Marboxil, in vitro and in mice. Antiviral Research. 2020; 179:104807.
https://www.sciencedirect.com/science/article/abs/pii/S0166354220302217?via%3Dihub
Nicolas de Lamballerie C, Pizzorno A, Dubois J, Padey B, Julien T, Traversier A, Carbonneau J, Orcel E, Lina B, Hamelin ME, Roche M, Textoris J, Boivin G, Legras-Lachuer C, Terrier O, Rosa-Calatrava M. Human Respiratory Syncytial Virus-induced immune signature of infection revealed by transcriptome analysis of clinical pediatric nasopharyngeal swab samples. Journal of Infectious Disease 2021 Mar 29;223(6):1052-1061.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8006426/
Checkmahomed L#, Padey B#, Pizzorno A, Terrier O, Rosa-Calatrava M, Baz M, Abed Y and Boivin G. In vitro combinations of baloxavir acid and other inhibitors against seasonal influenza A viruses Viruses 2020, 12, 1139. #Equal contribution
https://pubmed.ncbi.nlm.nih.gov/33049959/
Maisonnasse P, Guedj J, Behillil S, Contreras-Deves V, Solas C, Pizzorno MA, Naninck T, Lemaitre J, Gonçalves A, Marlin R, Kahlaoui N, Terrier O, Delache B, Ho Tsong Fang R, Dereuddre-Bosquet N, Chapon C, Hoen B, Sultan E, Lina B, Rosa Calatrava M, Van Der Werf S, De Lamballerie X, Le Grand R. Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non-human primates. Nature. 2020 585, pages584–587.
https://www.nature.com/articles/s41586-020-2558-4
Pizzorno A, Padey B, Dubois J, Julien T, Traversier A, Dulière* V, Brun P, Lina B, Terrier O, Rosa-Calatrava M. In vitro antiviral activity against SARS-CoV-2 of single and combined repurposable drugs. Antiviral research Volume 181, September 2020, 104878
https://pmc.ncbi.nlm.nih.gov/articles/PMC7361110/
Pizzorno A, Padey B, Julien T, Trouillet-Assant S, Traversier A, Errazuriz-Cerda E, Fouret J, Dubois J, Gaymard A, Lescure FX, Dulière V, Brun P, Constant S, Poissy J, Lina B, Yazdanpanah Y, Terrier O and Rosa-Calatrava M. Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. Cell Reports Medecine Volume 1, Issue 4, 21 July 2020, 100059.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7373044/
Dubois J, Pizzorno A, Cavanagh MH (CAN), Padey B, Nicolas de Lamballerie C, Uyar O, Venable MC, Carbonneau J, Traversier A, Julien T, Lavigne C, Couture C, Lina B, Hamelin ME, Terrier O, Rosa-Calatrava M# and Boivin G#. Strain-dependent impact of G and SH deletions provide new insights for live-attenuated HMPV vaccine development. NPJ Vaccines 2019, 7(4), 164. # equal contribution
https://pmc.ncbi.nlm.nih.gov/articles/PMC6963613/
Lê VB, Dubois J, Couture C, Cavanagh MH (CAN), Rosa-Calatrava M, Hamelin ME and Boivin G. Human Metapneumovirus Activates NOD-like Receptor Protein 3 Inflammasome via Its Small Hydrophobic Protein Which Plays a Detrimental Role during Infection in Mice. Plos Pathogens 2019 Apr 9;15(4):e1007689.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6474638/
Pizzorno A, Terrier O, Nicolas de Lamballerie C, Julien T, Padey B, Traversier A, Roche M, Hamelin ME, Rhéaume C, Croze S, Escuret V, Poissy J, Lina B, Legras-Lachuer C, Textoris J, Boivin G and Rosa-Calatrava M. Repurposing of drugs as novel influenza inhibitors from clinical gene expression infection signatures. Frontiers in Immunology, 2019 Jan 29;10:60.
https://pubmed.ncbi.nlm.nih.gov/30761132/
Mandon ED#, Pizzorno A#, Traversier A, Champagne A, Hamelin ME, Lina B, Boivin G, Dejean E, Rosa-Calatrava M##, Jawhari A##. Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection. Vaccine. 2019 Oct 17. S0264-410X(19)31381-7. * Co-premier auteurs ; # equal contribution ## equal contribution
https://www.sciencedirect.com/science/article/abs/pii/S0264410X19313817?via%3Dihub
Nicolas de Lamballerie C, Pizzorno A, Dubois J, Julien T, Padey B, Bouveret M, Traversier A, Legras-Lachuer C, Lina B, Boivin G, Terrier O, Rosa-Calatrava M. Characterization of cellular transcriptomic signatures induced by different respiratory viruses in human reconstituted airway epithelia. Scientific Reports. 2019 Aug 7;9(1):11493.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6685967/
Dubois J, Traversier A, Julien t, Padey B, Lina B, Bourdon JC, Marcel V, Boivin G, Rosa-Calatrava M# and Terrier O#. The non-structural NS1 protein of influenza viruses modulates TP53 splicing through the host factor CPSF4. Journal of Virology 2019 Mar 21;93(7). # equal contribution
https://pmc.ncbi.nlm.nih.gov/articles/PMC6430556/
del Campo J, Pizzorno A, Djebali S, Bouley J, Haller M, Pérez-Vargas J, Lina B, Boivin G, Hamelin ME, Leverrier Y, Rosa-Calatrava M, Marvel J, Hill F. OVX836: a novel recombinant nucleoprotein vaccine inducing CD4+ and CD8+ T cell responses and protective efficacy against multiple influenza A subtypes. NPJ Vaccines. 2019 Jan 23;4:4
https://pmc.ncbi.nlm.nih.gov/articles/PMC6344521/
Dubois J, Cavanagh M-H, Terrier O, Hamelin M-E, Lina B, Shi R, Rosa-Calatrava M and Boivin G. Mutations in the fusion protein heptad repeat domains of human metapneumovirus impact the formation of syncytia. Journal of General Virology. 2017 Jun;98(6):1174-1180.
https://www.microbiologyresearch.org/content/journal/jgv/10.1099/jgv.0.000796#tab2
Le Bayon JC, Lina B, Rosa-Calatrava M and Boivin G. Recent developments with live-attenuated recombinant paramyxovirus vaccines. Review in Medical Virology, 2012, May 8.
https://onlinelibrary.wiley.com/doi/10.1002/rmv.1717
Feuillet F, Lina B, Rosa-Calatrava M, Boivin G. Ten years of human métapneumovirus research. Journal of Clinical Virology, 2011. Feb;53(2):97-105
https://www.sciencedirect.com/science/article/abs/pii/S1386653211004185?via%3Dihub